WebbProthena Corp. Plc is a late-stage clinical biotechnology company, which research, development and commercialization of therapies in the neuroscience and orphan categories. Its antibody-based product candidates target a potential indications including amyloidosis and Parkinson's disease. Webb13 apr. 2024 · (0) (0) Prothena Corp. plc (PRTA) Stock Research Links PRTA Message Board Company Profile Time & Sales Recent News Filings Financials Buy Rating My Twitter: WhyteStocks Previous Investors Hangout Home Mailbox Message Boards Favorites Whats Hot Blog Settings Privacy Policy Terms and Conditions Disclaimer Contact Us Whats Hot …
Prothena Corporation plc Director, Patient Recruitment
WebbProthena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. WebbProthena’s wholly owned programs include birtamimab for the potential treatment of AL amyloidosis and a portfolio of programs for the potential treatment of Alzheimer’s … pelvic pain and stomach pain
Prothena Biosciences - expertise in protein dysregulation
Webb29 mars 2024 · During the last twelve months, Prothena insiders bought shares 1 times. They purchased a total of 1,062,736 shares worth more than $30,840,598.72. During the last twelve months, insiders at the biotechnology company sold shares 44 times. They sold a total of 452,243 shares worth more than $21,183,412.82. WebbProthena Corporation plc stock price live 49.94, this page displays NASDAQ PRTA stock exchange data. View the PRTA premarket stock price ahead of the market session or … Webb8 dec. 2024 · Prothena Corporation plc Ordinary Shares (PRTA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. mechanics tool set husky